Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A Phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma
Autore:
Kosmas, C; Tsavaris, NB; Polyzos, A; Kalofonos, HP; Sepsas, E; Malamos, NA; Vadiaka, M; Dosios, T; Antonopoulos, MJ;
Indirizzi:
Helena Venizelou Hosp, Med Oncol Unit, Athens, Greece Helena Venizelou Hosp Athens Greece osp, Med Oncol Unit, Athens, Greece Univ Athens, Laikon Gen Hosp, Sch Med, Med Oncol Unit, GR-11527 Athens, Greece Univ Athens Athens Greece GR-11527 d Oncol Unit, GR-11527 Athens, Greece Patras Univ Hosp, Dept Med Oncol, Patras, Greece Patras Univ Hosp PatrasGreece niv Hosp, Dept Med Oncol, Patras, Greece Chest Dis Hosp Athens, Dept Thorac Surg, Athens, Greece Chest Dis Hosp Athens Athens Greece s, Dept Thorac Surg, Athens, Greece Univ Athens, Laikon Gen Hosp, Sch Med, Dept Gen Surg, Athens, Greece Univ Athens Athens Greece Hosp, Sch Med, Dept Gen Surg, Athens, Greece
Titolo Testata:
CANCER
fascicolo: 4, volume: 89, anno: 2000,
pagine: 774 - 782
SICI:
0008-543X(20000815)89:4<774:APISOP>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; ONCOLOGY-GROUP; CLINICAL-TRIALS; SOLID TUMORS; CANCER; CARBOPLATIN; INFUSION; CHEMOTHERAPY; GEMCITABINE; VINORELBINE;
Keywords:
paclitaxel; ifosfamide; cisplatin; nonsmall cell lung carcinoma;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
38
Recensione:
Indirizzi per estratti:
Indirizzo: Kosmas, C 21 Apolloniou St, GR-16341 Athens, Greece 21 Apolloniou St Athens Greece GR-16341 R-16341 Athens, Greece
Citazione:
C. Kosmas et al., "A Phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma", CANCER, 89(4), 2000, pp. 774-782

Abstract

BACKGROUND. The necessity to develop more effective chemotherapy regimens in advanced nonsmall cell lung carcinoma (NSCLC) prompted the authors to evaluate the paclitaxel-ifosfamide-cisplatin (PIC) combination, developed on the basis of high individual single-agent activity, in vitro synergism, andtolerance as determined in a previous Phase I study by the authors. PATIENTS. Eligibility criteria included advanced NSCLC (American Joint Committee on Cancer [AJCC]/International Union Against Cancer [UICC] Stage III/IV), Eastern Cooperative Oncology Group performance status (PS) less than or equal to 2, no prior chemotherapy, and unimpaired hematopoietic and organ function. Chemotherapy included, paclitaxel 175 (in the first 10 patients) or 200 mg/m(2) on Day 1, ifosfamide: 5 g/m(2) divided over Days 1 and 2, and cisplatin 100 mg/m2 divided over Days 1 and 2, recycled every 21 days. Granulocyte-colony stimulating factor was administered from Day 4 to 13 or until leukocyte count reached greater than or equal to 10,000/mu L. RESULTS, Fifty patients were entered, and all were evaluable for response and toxicity: median age, 58 years (range, 40-72), PS, 1 (range, 0-2), Gender: 44 males and 6 females, Stages ILIA, 6 patients; IIIB, 17; IV, 27; histologies: adenocarcinoma, 27 patients; squamous, 17; large cells, 5; unspecified, 1. Metastatic sites at diagnosis included lymph nodes, 33 patients; bone, 6; liver, 5; brain, 10; lung nodules, 7; adrenals, 6; other, 2. Thirty-two of 50 (64%; confidence interval, 50.7-77.3%) evaluable patients responded: 4 complete remissions, 28 partial remissions, 13 stable disease, and 5progressive disease. The quality-of-life score improved in 37 of 50 (74%) patients. The median response duration was 7 months (range 2-34+); median time-to-progression, 8 months (range, 1-36+), median overall survival, 12 months (range, 2-36+). One-par survival was 53%. Grade 3 and 4 toxicities included neutropenia 38 of 50 patients with 21 developing Grade 4 neutropenia (less than or equal to 5 days) and 7 of these febrile neutropenia (144b); thrombocytopenia, 4 of 50 patients with 1 Grade 4 requiring platelet transfusions, 1 Grade 3 neuropathy; Grade 1-2 central nervous system toxicity due to ifosfamide was seen in 22 patients, no renal toxicity, 15 Grade 2 myalgias, 17 Grade 2 diarrhea, and 10 Grade 3 vomiting. CONCLUSIONS. The PIC combination appears highly active and tolerable in advanced NSCLC administered in the outpatient setting, Future randomized comparisons to other current standard regimens in NSCLC will be warranted. (C) 2000 American Cancer Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/09/20 alle ore 07:32:52